Clinical Trials Browser

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Phase 2 Active not recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06177067 2026-03-04

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Recruiting

24 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06390319 2026-02-27

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Phase 2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase 1 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Active not recruiting

37 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Clinical Trials

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia